Full-Time

Senior Scientist

Analytical Development & Quality Control

Posted on 1/17/2025

Altos Labs

Altos Labs

501-1,000 employees

Biotechnology focused on cell rejuvenation research

Compensation Overview

$165k - $277.2kAnnually

Senior

San Francisco, CA, USA

The job is located in the San Francisco Bay Area, CA, and there is a specific salary range mentioned for Redwood City, CA.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • Ph.D. in analytical sciences or biological sciences
  • Minimum 6+ years of analytical development and QC experience in biotech/pharmaceutical industry
  • Highly experienced in developing and implementing titer assays for biologics and/or AAV gene therapy products including DS/DP and residuals, and QC testing for release, in-process and stability
  • Proficient in phase appropriate qualification/validation requirements, cGMP’s and pharmaceutical industry procedures and regulations
  • Strong problem-solving skills with the ability to interpret complex data sets
  • Experienced in achieving CMC deliverables for QC assays outsourced to CROs
  • Knowledge of regulatory requirements and quality standards related to release of AAV DS/DP
  • Ability to work in a dynamic environment, with a willingness to learn new skills and adapt to shifting priorities and tasks
  • Excellent communication skills
  • Proven capability to collaborate effectively in a diverse, global, cross-functional structure and commit to diversity, equity, and belonging.
Responsibilities
  • Lead internal and/or external development of phase-appropriate capsid (Cp) titer, residuals as well as purity and impurity assays, with an initial focus on AAV gene therapy programs.
  • Design and develop assays for Cp titer by ELISA, Surface Plasma Resonance and/or SEC-HPLC, Purity assay by CE, Full/Empty capsid ratio by AEX and/or SEC-HPLC and/or charge detection mass spectrometry (CDMS).
  • Lead the timely transfer of the developed assay to external vendor/s as needed, and manage external assay development/qualification for release and stability testing at the CRO.
  • Serve as a technical expert in CMC-appropriate analytical assays for Vg and Cp titer, Full/Empty ratio and residuals, establishment of product specifications and OOS/OOT investigations.
  • Author, review, and/or approve Standard Operating Procedures, development reports, qualification protocols and reports, specifications, regulatory filing and/or other controlled documents.
  • Collaborate cross-functionally with process development, quality control, QA, Institutes of Science, development sciences, clinical, regulatory, program management, legal and finance.
  • Recruit and provide direction and training to development associates as the team expands.
  • Stay abreast of industry trends, emerging technologies, and regulatory guidelines to contribute to the continuous improvement of analytical methods, quality control and specifications.
  • Actively contribute to a team culture that promotes continuous improvement, ownership, professional growth, and inclusion.

Altos Labs specializes in biotechnology with a focus on cell rejuvenation, aiming to restore cell health and resilience to reverse diseases and injuries. They utilize cellular rejuvenation programming to enhance cells' ability to resist stressors that lead to illness. The company differentiates itself through its dedicated research and development efforts, collaborating with healthcare providers and research institutions to create effective treatments. Altos Labs' goal is to improve patients' quality of life by providing solutions that can alleviate the effects of various health conditions.

Company Size

501-1,000

Company Stage

Seed

Total Funding

$3.2B

Headquarters

Los Altos, California

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased investment in longevity research supports Altos Labs' growth potential.
  • Growing demand for innovative treatments positions Altos Labs at the market forefront.
  • AI and machine learning expedite the development of new cellular rejuvenation therapies.

What critics are saying

  • Ethical concerns about life extension may lead to regulatory challenges.
  • Intensifying competition in the biotech sector could dilute Altos Labs' market share.
  • Reliance on high-profile investors may pressure Altos Labs to deliver rapid results.

What makes Altos Labs unique

  • Altos Labs focuses on cellular rejuvenation to reverse diseases and improve healthspan.
  • The company collaborates with leading scientists and research centers for innovation.
  • Altos Labs leverages biotechnology to develop tailored cell rejuvenation therapies.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
The Spirits Business
Mar 27th, 2024
Altos is UK off-trade's leading 100% agave Tequila

In London, Altos recently launched its inaugural Margarita Masters competition for bartenders, with the hope of taking it nationwide in the future.

Startup Italia
Nov 17th, 2023
«Ad Altos Labs Vogliamo Creare Una Nuova Medicina». Simone Bianco E L’Avventura Nella Venture Californiana

«Per uno scienziato Elon Musk ha senz’altro meno appeal di un Premio Nobel». Se poi i Nobel sono quattro, tutti seduti nel board of directors della startup per cui lavori, potremmo dire non esserci partita. Tra questi, ad esempio, Jennifer Doudna, che ha vinto grazie al lavoro sull’editing genetico Crispr nel 2020. Simone Bianco, employee numero 27 di Altos Labs con sede a San Francisco, è Principal Investigator e Director of Computational Biology in quella che lui preferisce definire una venture, non una startup. Nel corso dell’intervista gli abbiamo chiesto di Musk e dei suoi piani per salvare l’umanità, anche con Neuralink, ma la discussione ha rapidamente virato verso altre figure, più specializzate nella materia in questione. Altos Labs, dunque

The Recursive
Mar 8th, 2023
Finding The Fountain Of Youth: Meet The Startups Pioneering Longevity Solutions

If technology allowed humanity to live forever in the future, would you take the ticket? We asked our readers recently and were surprised to see the balance tilt towards “No” (60% of respondents). One answer was hidden in a comment from one of our readers – they would want to live forever, yet only if they stayed young. Among others, living long worries people as it is associated with getting old and suffering from various diseases.Yet if technology allows us to extend our life spans it will also likely improve our health spans. According to demographers, children today have a better chance of living up to 100 years old than ever before. But their lives won’t be just longer, they will also benefit from day-to-day technological advances aimed at improving their well-being, preventing diseases, and keeping their minds and bodies in shape.Slowing aging presents an economic opportunity, too. In the US, an estimate shows that just one to two years increase in life expectancy are worth between $7 trillion and $38 trillion

GeekWire
Apr 21st, 2022
Juno Therapeutics Vets Steve Harr And Hans Bishop On Building Startups, Working With Tech, And More

Hans Bishop and Steve Harr know a few things about biotech. The pair once worked together at Seattle flagship cell therapy company Juno Therapeutics, where Bishop was CEO and Harr was COO and CFO.

Fierce Biotech
Apr 18th, 2022
Biotech's top 10 money raisers of 2021

After a bustling, record-setting 2020 for private biotechs raising cash, the bar heading into 2021 was exceptionally high. Turns out, private investors elected to just take the bar and do pull-ups, breaking 2020’s record by a whopping 26%.  | 2021 marked the second consecutive year of record-breaking private financing for biotechs, with more than $28 billion raised. The total haul is a 26% increase from 2020, and the stunning dollar amounts came even as the public market depreciated throughout the year. Here's our look at the 10 biotechs that raked in the largest VC investments.

INACTIVE